Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Edesa Biotech Inc (EDSA)

Edesa Biotech Inc (EDSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,008
  • Shares Outstanding, K 15,462
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,340 K
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.20
Trade EDSA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.34
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.43
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -25.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +22.22%
on 09/30/22
1.8500 -40.54%
on 09/06/22
-0.6600 (-37.50%)
since 09/02/22
3-Month
0.9000 +22.22%
on 09/30/22
2.4609 -55.30%
on 08/08/22
-0.5000 (-31.25%)
since 07/01/22
52-Week
0.9000 +22.22%
on 09/30/22
8.9500 -87.71%
on 11/03/21
-6.0700 (-84.66%)
since 10/04/21

Most Recent Stories

More News
Edesa Biotech to Present at ARDS Drug Development Summit

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan,...

EDSA : 1.1100 (+0.91%)
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company...

EDSA : 1.1100 (+0.91%)
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan,...

EDSA : 1.1100 (+0.91%)
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results...

EDSA : 1.1100 (+0.91%)
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

EDSA : 1.1100 (+0.91%)
Edesa Biotech Appoints Strategy Expert to Board of Directors

TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment...

EDSA : 1.1100 (+0.91%)
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing...

EDSA : 1.1100 (+0.91%)
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has...

EDSA : 1.1100 (+0.91%)
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update...

EDSA : 1.1100 (+0.91%)
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...

EDSA : 1.1100 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.4208
2nd Resistance Point 1.2854
1st Resistance Point 1.1927
Last Price 1.1100
1st Support Level 0.9646
2nd Support Level 0.8292
3rd Support Level 0.7365

See More

52-Week High 8.9500
Fibonacci 61.8% 5.8749
Fibonacci 50% 4.9250
Fibonacci 38.2% 3.9751
Last Price 1.1100
52-Week Low 0.9000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar